Floatz logo

ibi310

NSCLC (Non-small-cell Lung Cancer)

Shanghai Pulmonary Hospital, Shanghai, Chinamonoclonal_antibodyPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

1205 Active assets in the NSCLC (Non-small-cell Lung Cancer) cohort.

Asset / SponsorPhaseRating
Necitumumab
Jonsson Comprehensive Cancer Center
Phase 3BBB
Zorifertinib
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3BBB
Glumetinib
Shanghai JMT-Bio Inc.
Phase 3BBB
d-0316
Betta Pharmaceuticals Co., Ltd.
Phase 2/3BBB
Onartuzumab
Hoffmann-La Roche
Phase 3BBB

View all 50 →

Same molecule, other indications

ibi310 is also rated in:

hepatocellular carcinomaDormant
B
Indicative ·
62 / 100
View asset →
acral lentiginous melanomaDormant
B
Indicative ·
60 / 100
View asset →
MSI-HDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →